A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

被引：0
|
作者：
Oh, Stephen [1 ]
Kiladjian, Jean-Jacques [2 ]
Palandri, Francesca [3 ]
Gotlib, Jason [4 ]
Mohan, Sanjay [5 ]
Ali, Haris [6 ]
Asatiani, Ekatherine [7 ]
Seguy, Francis [7 ]
Zhou, Feng [8 ]
Verstovsek, Srdan [9 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Univ Paris, INSERM, Hop St Louis, AP HP, Paris, France
[3] Azienda Osped Univ Bologna, IRCCS Ist Ricovero & Cura Carattere Sci, Policlin S Orsola Malpighi, Bologna, Italy
[4] Stanford Canc Inst, Stanford, CA USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] City Hope Med Ctr, Duarte, CA USA
[7] Incyte Biosci Int Sarl, Morges, Switzerland
[8] Incyte Corp, Wilmington, DE USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH2021-PO
引用
收藏
页码：111 / 112
页数：2
相关论文
共 50 条
  • [41] INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)
    Fujiwara, Yutaka
    Shitara, Kohei
    Shimizu, Toshio
    Yonemori, Kan
    Matsubara, Nobuaki
    Ohno, Izumi
    Kogawa, Takahiro
    Naito, Yoichi
    Leopold, Lance
    Sasahara, Kahori
    Yatsuzuka, Naoyoshi
    Takami, Tomoko
    Shimamoto, Takashi
    Yamamoto, Noboru
    Doi, Toshihiko
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [42] Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis
    Verstovsek, Srdan
    Yeleswaram, Swamy
    Hou, Kevin
    Chen, Xuejun
    Erickson-Viitanen, Sue
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (04) : 701 - 708
  • [43] Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies
    Patel, Manish R.
    Donnellan, William
    Byrne, Michael
    Asch, Adam S.
    Zeidan, Amer M.
    Baer, Maria R.
    Fathi, Amir T.
    Kuykendall, Andrew T.
    Zheng, Fred
    Walker, Chris
    Cheng, Lulu
    Marando, Cindy
    Savona, Michael R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (09): : 674 - 686
  • [44] Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study
    Watts, Justin M.
    Vannucchi, Alessandro M.
    Hunter, Anthony M.
    McMahon, Brandon
    Tantravahi, Srinivas K.
    Iurlo, Alessandra
    Xicoy, Blanca
    Palandri, Francesca
    Searle, Emma
    Reeves, Brandi N.
    Bose, Prithviraj
    Ayala, Rosa
    Halpern, Anna B.
    Chen, Xuejun
    Burke, Lea M.
    Zhou, Feng
    Zheng, Fred
    Vachhani, Pankit
    BLOOD, 2023, 142
  • [45] A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL)
    Forero-Torres, Andres
    Barr, Paul M.
    Diefenbach, Catherine S. Magid
    Sher, Taimur
    Schaub, Richard
    Zhou, Li
    Pulini, Jennifer
    Leopold, Lance
    Spear, Matthew A.
    Talpaz, Moshe
    Phillips, Tycel Jovelle
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
    Gupta, Vikas
    Harrison, Claire N.
    Hasselbalch, Hans
    Pieri, Lisa
    Koschmieder, Steffen
    Cervantes, Francisco
    Bao, Weichao
    Kalambakas, Stacey
    Atienza, Edric
    Gopalakrishna, Prashanth
    Heidel, Florian H.
    BLOOD, 2015, 126 (23)
  • [47] Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia - Final Results of a Prospective Phase 2 Study
    Masarova, Lucia
    Daver, Naval G.
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Jabbour, Elias J.
    Zhou, Lingsha
    Pierce, Sherry A.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [48] BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
    Ayala, Rosa
    Lopez, Nieves
    Abulafia, Adi Shacham
    Alwan, Maan
    Yannakou, Costas K.
    Raman, Indu
    Ribrag, Vincent
    Fong, Chun Yew
    Volchek, Yulia
    Bonifacio, Massimiliano
    Tucci, Alessandra
    Kiladjian, Jean-Jacques
    Chang, Henry
    Das, Sharmila
    Wu, Bin
    Ravindran, Palanikumar
    Shan, Vivian
    Wang, Guan
    Esposito, Oriana
    Liu, Yu
    Nikolova, Zariana
    Tehlirian, Christopher
    Coker, Shodeinde
    Lavie, David
    BLOOD, 2022, 140 : 9665 - 9667
  • [49] A randomized, placebo-controlled, phase 2 study of the Janus Kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa
    Alavi, Afsaneh
    Hamzavi, Iltefat
    Brown, Kurt
    Santos, Leandro L.
    Zhu, Zhaoyin
    Howell, Michael D.
    Kirby, Joslyn
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 69 - 70
  • [50] A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis
    Mascarenhas, John O.
    Rampal, Raajit
    El Chaer, Firas
    Gupta, Vikas
    Shimoda, Kazuya
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Bose, Prithviraj
    Scandura, Joseph M.
    Mesa, Ruben
    Rein, Lindsay A. M.
    Yuda, Junichiro
    Ross, David M.
    Devos, Timothy
    Talpaz, Moshe
    Hoffman, Ronald
    Kabir, Sujan
    Li, Zhonggai
    Foulks, Jason M.
    Ansaldo, Karen
    Seki, Masataka
    Peddagali, Vishnu
    Shah, Jatin
    Harrison, Claire
    BLOOD, 2024, 144 : 6629 - 6631
12345